Latest / Stock Movers / Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 1: Nathan Hager looking for some stocks on the move today. Nathan,
- 0:20Speaker 1: what do you got for us stock that is seriously
- 0:23Speaker 1: on the move this morning? Poul is Appage Therapeutics. This
- 0:27Speaker 1: is on some merger Monday news, the ticker APGE. The
- 0:31Speaker 1: stock is up nearly forty seven percent pre market. It's
- 0:35Speaker 1: around one hundred and thirty two dollars to share. This
- 0:37Speaker 1: is because ABV is buying Appage for ten point nine
- 0:42Speaker 1: billion dollars, one of the biggest deals for ABVI since
- 0:45Speaker 1: it bought Allergan six years ago for sixty three large
- 0:49Speaker 1: That brought Botox into the ABVI portfolio, but since then
- 0:53Speaker 1: it's been facing some competition in the anti inflammatory space
- 0:57Speaker 1: for its blockbuster psoriasis sky Rizzy. So what's it get
- 1:01Speaker 1: out of APAGEE. Well, that company's got a promising experimental
- 1:05Speaker 1: compound for piriasis whose name I'm not even going to
- 1:09Speaker 1: try to pronounce, though it could be a rival to
- 1:12Speaker 1: France's santafi at its blockbuster due pix. It another name
- 1:17Speaker 1: you're probably very familiar with.
- 1:19Speaker 2: Now.
- 1:19Speaker 1: Avi says this acquisition is going to give it the size,
- 1:22Speaker 1: scale and expertise to address some of the most complex
- 1:26Speaker 1: diseases in immunology. So, like I say, appage shares hire
- 1:30Speaker 1: by forty seven percent. Santa Fee, by the way in
- 1:34Speaker 1: Paris down three percent.
- 1:37Speaker 2: What about your next talk.
- 1:38Speaker 1: It's also tricky to pronounce. I'm also not going to
- 1:40Speaker 1: try to pronounce it, Nathan. Yeah. Well, there's a lot
- 1:43Speaker 1: going on in the pharma space, Isabelle. This one is
- 1:46Speaker 1: regen x Bio. The ticker there is rgnx, and the
- 1:50Speaker 1: shares are hired by about twelve percent pre market. This
- 1:54Speaker 1: is on a report from the Wall Street Journal that
- 1:55Speaker 1: the Food and Drug Administration's actually agreed to reverse its
- 1:59Speaker 1: rejection of regen x bios experimental gene therapy for a
- 2:03Speaker 1: rare and deadly brain disease, the latest about face for
- 2:07Speaker 1: the FDA after the departure of its former Vaccine and
- 2:10Speaker 1: Biotech division leader Vene Prosad. When he was in charge,
- 2:13Speaker 1: FDA was demanding that rare disease drug makers like regen
- 2:17Speaker 1: x bio test their drugs against placebos, but the drug
- 2:21Speaker 1: makers have been arguing that's not practical when you're talking
- 2:24Speaker 1: about experimental treatments for patients that might only be a
- 2:28Speaker 1: few dozen a year. And in this case, regen X
- 2:31Speaker 1: is therapy known as nav sunly targets what's known as
- 2:35Speaker 1: Hunter syndrome. This is a rare genetic disease that's diagnosed
- 2:39Speaker 1: in about fifty US patients each year, nearly all of
- 2:42Speaker 1: them boys. That causes irreversible and in many cases, deadly
- 2:47Speaker 1: brain damage. Now, Regenics's CEO says it's going to refile
- 2:51Speaker 1: its application with the FDA in the third quarter after
- 2:53Speaker 1: meeting with the regulator to resolve disputes, and that meeting
- 2:56Speaker 1: is expected to happen next month. But in the meantime,
- 3:00Speaker 1: gen X bioshares are surging pre market. All right, lastly,
- 3:03Speaker 1: let's go to SpaceX. Yeah, I got to talk about
- 3:06Speaker 1: this one. The ticker of course, SPCX. It's indicated to
- 3:10Speaker 1: open four percent lower, adding to the two straight sessions
- 3:14Speaker 1: of declines we've seen since the huge post IPO gain.
- 3:18Speaker 1: But Elon Musk's Rocket AI company is officially getting into
- 3:22Speaker 1: the investment grade bond market, kicking off its inaugural offering
- 3:25Speaker 1: of senior unsecured notes.
- 3:27Speaker 2: Now.
- 3:27Speaker 1: We'd reported last week that SpaceX planned to raise about
- 3:30Speaker 1: twenty billion dollars from this offer to set up a
- 3:32Speaker 1: temporary bridge loan that's going to make up the bulk
- 3:35Speaker 1: of its long term debt. SpaceX has five of the
- 3:38Speaker 1: six biggest banks on Wall Street kicking off marketing for
- 3:41Speaker 1: these bonds, the only one left in the cold, as
- 3:43Speaker 1: well as Fargo, but this is likely to be the
- 3:46Speaker 1: start of a massive borrowing spree to finance Elon Musk's
- 3:50Speaker 1: AI ambitions for the Rocket Company. In the kickoff of
- 3:54Speaker 1: the bond sale, the company disclosed that it's already sitting
- 3:57Speaker 1: on about one hundred billion dollars in cash and looking
- 4:00Speaker 1: for even more.
- 4:03Speaker 2: This stockmover's report from Bloomberg Radio. Check back with us
- 4:07Speaker 2: throughout the day for the latest roundup of companies making
- 4:10Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:14Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 4:18Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:21Speaker 2: Bloomberg Business app.